Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > LATEST
LATEST
-
BUSINESS Gilead Paints Sustained Growth Curve with Trodelvy, CAR-T Therapies
October 2, 2026
-
REGULATORY US Narrows Scope of Medicare MFN Model, Exempts Orphan-Only Drugs
October 2, 2026
-
BUSINESS CSL Behring Japan Names Edward Wright as New Chief
October 2, 2026
-
ORGANIZATION 60% of EFPIA Firms Could Cut Japan Trial Investments without Policy Reform
October 2, 2026
-
BUSINESS Takeda Welcomes 39 Prospective 2027 Hires in Japan
October 2, 2026
-
REGULATORY Japan to Draw Up Growth Strategy Action Plan by Year-End
October 2, 2026
-
BUSINESS Nippon Shinyaku Reports 5-Year Efficacy Data for DMD Hopeful
October 2, 2026
-
BUSINESS Taiho’s ASTX030 Hits PIII Goal, US Filing Planned
October 2, 2026
-
BUSINESS Ono Moves US Venture Capital Arm to Cambridge
October 2, 2026
-
BUSINESS Toho Confirms Preliminary Bid for PHC as It Mulls Buyout
October 2, 2026
-
REGULATORY Chuikyo Backs Broader CEA Price Cuts This Year, Snubs Pharma Plea
October 1, 2026
-
BUSINESS Novo Expands Oral Obesity Arsenal, Hengrui Asset Eyed around 2030
October 1, 2026
-
BUSINESS Bayer Takes Dialogue-Driven Innovation Model Nationwide
October 1, 2026
-
BUSINESS Chugai to Set Up South Korea Unit, Take Sales In-House
October 1, 2026
-
BUSINESS Daito Reveals Meiji, DBJ as Partners in Kyorin Generics JV
October 1, 2026
-
BUSINESS Sumitomo Universal Flu Vaccine Shows Favorable Safety in Europe PI
October 1, 2026
-
BUSINESS Rohto Wins Japan Sales Rights to PharmaBio’s Cell Sheet
October 1, 2026
-
REGULATORY Repatha Optimal Use Guidelines to Be Simplified
October 1, 2026
-
BUSINESS Asahi Kasei Rebrands Pharma Units under Common Global Name
September 30, 2026
-
ORGANIZATION JPMA to Complete Shift to Legal Entity on October 1
September 30, 2026
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…